Fagron NV (ARSUF)
27.50
0.00 (0.00%)
USD |
OTCM |
Oct 07, 16:00
Fagron Max Drawdown (5Y) : 49.81% for Sept. 30, 2026
Max Drawdown (5Y) Chart
Historical Max Drawdown (5Y) Data
| Date | Value |
|---|---|
| September 30, 2026 | 49.81% |
| August 31, 2026 | 49.81% |
| July 31, 2026 | 49.81% |
| June 30, 2026 | 49.81% |
| May 31, 2026 | 49.81% |
| April 30, 2026 | 49.81% |
| March 31, 2026 | 49.81% |
| February 28, 2026 | 49.81% |
| January 31, 2026 | 49.81% |
| December 31, 2025 | 49.81% |
| November 30, 2025 | 49.81% |
| October 31, 2025 | 49.81% |
| September 30, 2025 | 49.81% |
| August 31, 2025 | 49.81% |
| July 31, 2025 | 49.81% |
| June 30, 2025 | 49.81% |
| May 31, 2025 | 49.81% |
| April 30, 2025 | 49.81% |
| March 31, 2025 | 69.93% |
| February 28, 2025 | 69.93% |
| January 31, 2025 | 69.93% |
| December 31, 2024 | 69.93% |
| November 30, 2024 | 69.93% |
| October 31, 2024 | 69.93% |
| September 30, 2024 | 69.93% |
| Date | Value |
|---|---|
| August 31, 2024 | 69.93% |
| July 31, 2024 | 69.93% |
| June 30, 2024 | 69.93% |
| May 31, 2024 | 69.93% |
| April 30, 2024 | 69.93% |
| March 31, 2024 | 69.93% |
| February 29, 2024 | 69.93% |
| January 31, 2024 | 69.93% |
| December 31, 2023 | 72.77% |
| November 30, 2023 | 72.77% |
| October 31, 2023 | 72.77% |
| September 30, 2023 | 72.77% |
| August 31, 2023 | 72.77% |
| July 31, 2023 | 72.77% |
| June 30, 2023 | 72.77% |
| May 31, 2023 | 72.77% |
| April 30, 2023 | 72.77% |
| March 31, 2023 | 72.77% |
| February 28, 2023 | 75.95% |
| January 31, 2023 | 75.95% |
| December 31, 2022 | 77.83% |
| November 30, 2022 | 77.83% |
| October 31, 2022 | 77.83% |
| September 30, 2022 | 77.83% |
| August 31, 2022 | 77.83% |
Max Drawdown Definition
Max drawdown is an indicator of the risk of a portfolio chosen based on a certain strategy. It measures the largest single drop from peak to bottom in the value of a portfolio before a new peak is achieved.
Max Drawdown (5Y) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Max Drawdown (5Y) Benchmarks
| PD-Rx Pharmaceuticals, Inc. | 100.0% |
| Lakefront Biotherapeutics | 91.72% |
| UCB SA | 50.06% |
| Acro Biomedical Co. Ltd. | 99.99% |
| Stella Diagnostics, Inc. | 99.58% |
Max Drawdown (5Y) Related Metrics
| Alpha (5Y) | 3.726 |
| Beta (5Y) | -0.0249 |
| Annualized Standard Deviation of Monthly Returns (5Y Lookback) | 28.09% |
| Historical Sharpe Ratio (5Y) | 0.1238 |
| Historical Sortino (5Y) | 0.2008 |
| Monthly Value at Risk (VaR) 5% (5Y Lookback) | 6.11% |